{"gene":"COX4I2","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":2009,"finding":"COX4I2 is an essential structural subunit of cytochrome c oxidase (Complex IV) with tissue-specific expression; its ratio to COX4I1 is relatively high in human acinar cells, and loss-of-function mutation causes marked reduction of COX4I2 expression and striking attenuation of the physiologic COX4I2 hypoxic response, linking it to mitochondrial respiratory chain function.","method":"Homozygosity mapping, mRNA expression analysis, mutation analysis in patient-derived cells","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 — direct genetic and expression evidence in human patients with defined loss-of-function phenotype, replicated across four patients","pmids":["19268275"],"is_preprint":false},{"year":2023,"finding":"SIRT3 deacetylates COX4I2 as a post-translational modification to maintain mitochondrial respiratory chain homeostasis; loss of SIRT3 leads to hyperacetylation of COX4I2 and impaired mitochondrial function, accelerating osteoarthritis progression.","method":"Co-immunoprecipitation, deacetylation assay, SIRT3 global knockout mice, honokiol-mediated SIRT3 activation rescue experiments","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP identifying SIRT3 as the writer for COX4I2 deacetylation, combined with in vivo KO phenotype and pharmacological rescue","pmids":["36683245"],"is_preprint":false},{"year":2021,"finding":"Cox4i2 increases COX (cytochrome c oxidase) activity in Schwann cells, thereby promoting ROS production; knockdown of Cox4i2 reduces oxidative stress, attenuates ferroptosis and apoptosis via the ERK signaling pathway in HHV7-infected Schwann cells.","method":"shRNA knockdown, ROS level measurement, MDA/SOD/GSH assays, cell death and proliferation assays, ERK pathway analysis in vitro and in vivo rat model","journal":"Frontiers in molecular biosciences","confidence":"Medium","confidence_rationale":"Tier 2 — KD with defined cellular phenotype and pathway placement (ERK), but single lab study","pmids":["34026834"],"is_preprint":false},{"year":2024,"finding":"HIF1A transcriptionally regulates COX4I2 expression by binding to its promoter; activation of HIF1A upregulates COX4I2, and this axis promotes angiogenesis through fibroblasts (not tumor cells directly) in pheochromocytoma.","method":"Dual luciferase reporter assay, siRNA knockdown, HIF1A inhibitor, hypoxia (1% O2) activation, conditioned medium tube formation and transwell assays in HUVECs, RNA sequencing","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase reporter assay directly demonstrates HIF1A binding to COX4I2 promoter, with functional angiogenesis readout; single lab","pmids":["38422899"],"is_preprint":false},{"year":2025,"finding":"Rpl13a snoRNA U32A guides 2'-O-methylation of COX4I2 mRNA, reducing COX4I2 protein levels post-transcriptionally without changing mRNA levels; loss of snoRNA U32A increases COX4I2 protein, reduces mitochondrial ROS in smooth muscle cells, and attenuates neointimal hyperplasia; silencing Cox4i2 in snoKO SMCs restores ROS to wild-type levels.","method":"snoRNA knockout mice (carotid endothelial denudation model), HEK293T snoRNA-specific deletion cells, 2'-O-methylation assay, siRNA silencing of Cox4i2, proteomics, Western blot, qPCR","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis (snoKO + Cox4i2 silencing rescue), direct 2'-O-methylation mechanistic assay, and in vivo neointimal hyperplasia model; preprint only","pmids":["40777413"],"is_preprint":true},{"year":2024,"finding":"EBF1 transcriptionally upregulates COX4I2 expression in cancer-associated fibroblasts (CAFs); COX4I2+ CAFs exhibit inhibited mitochondrial respiration and enhanced glycolysis, adopt a myofibroblast-like phenotype, promote immunosuppressive tumor microenvironment, and activate M2 macrophage polarization.","method":"Luciferase reporter assay, transcriptome sequencing, functional in vitro experiments (CD8+ T cell infiltration assay), clinical specimens","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2/3 — luciferase reporter validates EBF1-COX4I2 transcriptional axis; functional cellular phenotypes measured; single lab","pmids":["39002521"],"is_preprint":false},{"year":2022,"finding":"COX4I2 expressed in fibroblasts (not tumor cells) mediates angiogenesis in pheochromocytoma; knockdown of COX4I2 in NIH3T3 fibroblasts significantly reduces expression of angiogenesis-related genes ANG1 and HGF.","method":"scRNA-seq, immunostaining, siRNA knockdown in NIH3T3 cells, qPCR for angiogenesis-related genes","journal":"Frontiers in oncology","confidence":"Low","confidence_rationale":"Tier 3 — single lab, KD with gene expression readout but limited mechanistic depth","pmids":["36172142"],"is_preprint":false},{"year":2025,"finding":"Exosome-mediated delivery of COX4I2 protein from cancer-associated fibroblasts to osteosarcoma cells suppresses ferroptosis (reduces Fe2+, MDA, ACSL4, and ROS levels) and enhances tumor cell proliferation and mitochondrial integrity in vitro and in vivo.","method":"Western blot, confocal microscopy, transmission electron microscopy (exosome characterization), ferroptosis marker assays, tumorigenicity assays in nude mice","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods including in vivo validation and direct exosomal transfer demonstration; single lab","pmids":["40977891"],"is_preprint":false}],"current_model":"COX4I2 is an isoform-specific structural subunit of mitochondrial cytochrome c oxidase (Complex IV) that modulates electron transport chain activity and ROS production; it is transcriptionally induced by HIF1A and EBF1 under hypoxia, post-translationally regulated by SIRT3-mediated deacetylation, and post-transcriptionally suppressed by Rpl13a snoRNA U32A-guided 2'-O-methylation of its mRNA, with its activity in fibroblasts promoting angiogenesis and its activity in multiple cell types influencing ferroptosis, apoptosis, and mitochondrial homeostasis."},"narrative":{"teleology":[{"year":2009,"claim":"Establishing that COX4I2 is an essential, tissue-specific Complex IV subunit whose loss-of-function causes human disease resolved the question of whether isoform-specific subunits have non-redundant physiological roles in the mitochondrial respiratory chain.","evidence":"Homozygosity mapping and mutation analysis in four patients with pancreatic acinic cell dysplasia showing marked COX4I2 reduction and loss of hypoxic response","pmids":["19268275"],"confidence":"High","gaps":["The structural basis for how COX4I2 differs functionally from COX4I1 at the atomic level is unresolved","Whether the hypoxic response of COX4I2 is solely transcriptional or also involves protein stabilization was not dissected"]},{"year":2021,"claim":"Demonstrating that COX4I2 promotes ROS production and downstream ferroptosis/apoptosis via ERK signaling in Schwann cells established a mechanistic link between this Complex IV subunit and programmed cell death pathways.","evidence":"shRNA knockdown of Cox4i2 in HHV7-infected Schwann cells with ROS, MDA/SOD/GSH, cell death, and ERK pathway measurements","pmids":["34026834"],"confidence":"Medium","gaps":["Whether COX4I2 directly alters ERK signaling or does so indirectly through ROS is not resolved","Relevance beyond the HHV7 infection context has not been tested"]},{"year":2022,"claim":"Identifying COX4I2 expression specifically in fibroblasts (not tumor cells) as a mediator of angiogenesis in pheochromocytoma revealed an unexpected non-cell-autonomous role for a respiratory chain subunit in paracrine vascular regulation.","evidence":"scRNA-seq and siRNA knockdown in NIH3T3 fibroblasts measuring ANG1 and HGF expression","pmids":["36172142"],"confidence":"Low","gaps":["Limited mechanistic depth: only qPCR readout for two genes without direct angiogenesis functional assay","The mechanism by which COX4I2 regulates ANG1/HGF transcription is unknown"]},{"year":2023,"claim":"Showing that SIRT3 deacetylates COX4I2 and that hyperacetylation impairs mitochondrial function identified a key post-translational regulatory axis controlling Complex IV activity.","evidence":"Reciprocal Co-IP, deacetylation assays, SIRT3 knockout mice with osteoarthritis phenotype, and honokiol pharmacological rescue","pmids":["36683245"],"confidence":"High","gaps":["The specific lysine residue(s) on COX4I2 targeted by SIRT3 are not mapped","Whether acetylation affects COX4I2 assembly into Complex IV or its catalytic function is unresolved"]},{"year":2024,"claim":"Demonstrating that HIF1A directly binds the COX4I2 promoter and that EBF1 independently activates COX4I2 transcription defined dual transcriptional inputs that control COX4I2 in hypoxia and in the tumor microenvironment, respectively.","evidence":"Dual luciferase reporter assays for both HIF1A and EBF1 on the COX4I2 promoter; siRNA and inhibitor experiments; conditioned medium angiogenesis assays (HIF1A); transcriptome sequencing and immune cell infiltration assays (EBF1)","pmids":["38422899","39002521"],"confidence":"Medium","gaps":["Whether HIF1A and EBF1 act on the same or distinct promoter elements is not resolved","How COX4I2 upregulation in fibroblasts switches metabolism toward glycolysis (EBF1 axis) is mechanistically unclear"]},{"year":2025,"claim":"Identifying snoRNA U32A-guided 2′-O-methylation of COX4I2 mRNA as a translational repression mechanism, and showing exosome-mediated intercellular transfer of COX4I2 protein, expanded the regulatory landscape to post-transcriptional and non-cell-autonomous dimensions.","evidence":"snoRNA knockout mice and HEK293T cells with 2′-O-methylation assays and Cox4i2 epistasis experiments (U32A); exosome isolation, confocal imaging, ferroptosis marker assays, and nude mouse tumorigenicity (exosomal transfer)","pmids":["40777413","40977891"],"confidence":"Medium","gaps":["The U32A/COX4I2 mRNA methylation finding is from a preprint and awaits peer review","The precise methylation site(s) on COX4I2 mRNA and the ribosomal mechanism of translational suppression are not defined","Whether exosomal COX4I2 integrates into recipient cell Complex IV or functions independently is unknown"]},{"year":null,"claim":"How COX4I2 structurally integrates into Complex IV differently from COX4I1 to generate distinct ROS outputs, and how its context-dependent effects on ferroptosis (pro- vs. anti-ferroptotic) are determined, remain open questions.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model distinguishing COX4I2 from COX4I1 within assembled Complex IV","Opposing effects on ferroptosis across cell types (promoting in Schwann cells, suppressing in osteosarcoma) lack a unifying mechanistic explanation","The full acetylation site map and its effect on COX4I2 assembly and activity is uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,2,4]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,2]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0,2,4]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,7]}],"complexes":["Cytochrome c oxidase (Complex IV)"],"partners":["SIRT3","HIF1A","EBF1"],"other_free_text":[]},"mechanistic_narrative":"COX4I2 is a tissue-specific isoform of the nuclear-encoded subunit IV of mitochondrial cytochrome c oxidase (Complex IV) that modulates electron transport chain activity and reactive oxygen species (ROS) production. Its expression is transcriptionally regulated by HIF1A under hypoxia and by EBF1 in cancer-associated fibroblasts, post-translationally controlled by SIRT3-mediated deacetylation that maintains mitochondrial respiratory homeostasis, and post-transcriptionally suppressed by Rpl13a snoRNA U32A-guided 2′-O-methylation of its mRNA [PMID:19268275, PMID:38422899, PMID:39002521, PMID:36683245, PMID:40777413]. Through its regulation of COX activity and ROS levels, COX4I2 influences ferroptosis, apoptosis, and angiogenesis in cell-type-specific contexts: it promotes ROS-driven ferroptosis in Schwann cells via ERK signaling, drives fibroblast-mediated angiogenesis in pheochromocytoma, and when delivered by exosomes from cancer-associated fibroblasts suppresses ferroptosis in osteosarcoma cells [PMID:34026834, PMID:36172142, PMID:40977891]. Loss-of-function mutations in COX4I2 cause pancreatic acinic cell dysplasia with attenuated hypoxic COX4I2 induction [PMID:19268275]."},"prefetch_data":{"uniprot":{"accession":"Q96KJ9","full_name":"Cytochrome c oxidase subunit 4 isoform 2, mitochondrial","aliases":["Cytochrome c oxidase subunit IV isoform 2","COX IV-2"],"length_aa":171,"mass_kda":20.0,"function":"Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over the inner membrane that drives transmembrane transport and the ATP synthase. Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Electrons originating from reduced cytochrome c in the intermembrane space (IMS) are transferred via the dinuclear copper A center (CU(A)) of subunit 2 and heme A of subunit 1 to the active site in subunit 1, a binuclear center (BNC) formed by heme A3 and copper B (CU(B)). The BNC reduces molecular oxygen to 2 water molecules using 4 electrons from cytochrome c in the IMS and 4 protons from the mitochondrial matrix","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/Q96KJ9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/COX4I2","classification":"Not Classified","n_dependent_lines":13,"n_total_lines":1208,"dependency_fraction":0.01076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/COX4I2","total_profiled":1310},"omim":[{"mim_id":"620803","title":"HIG1 HYPOXIA-INDUCIBLE DOMAIN FAMILY, MEMBER 1C; HIGD1C","url":"https://www.omim.org/entry/620803"},{"mim_id":"616244","title":"COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 2; CHCHD2","url":"https://www.omim.org/entry/616244"},{"mim_id":"612752","title":"CXXC FINGER PROTEIN 5; CXXC5","url":"https://www.omim.org/entry/612752"},{"mim_id":"612714","title":"EXOCRINE PANCREATIC INSUFFICIENCY, DYSERYTHROPOIETIC ANEMIA, AND CALVARIAL HYPEROSTOSIS","url":"https://www.omim.org/entry/612714"},{"mim_id":"607976","title":"CYTOCHROME c OXIDASE, SUBUNIT 4I2; COX4I2","url":"https://www.omim.org/entry/607976"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":48.5},{"tissue":"placenta","ntpm":108.4}],"url":"https://www.proteinatlas.org/search/COX4I2"},"hgnc":{"alias_symbol":["COXIV-2","COX4B","dJ857M17.2","COX4-2"],"prev_symbol":["COX4L2"]},"alphafold":{"accession":"Q96KJ9","domains":[{"cath_id":"1.10.442.10","chopping":"41-97","consensus_level":"medium","plddt":88.2677,"start":41,"end":97},{"cath_id":"-","chopping":"131-171","consensus_level":"medium","plddt":93.4144,"start":131,"end":171},{"cath_id":"1.20.5","chopping":"99-128","consensus_level":"medium","plddt":95.8407,"start":99,"end":128}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96KJ9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96KJ9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96KJ9-F1-predicted_aligned_error_v6.png","plddt_mean":79.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=COX4I2","jax_strain_url":"https://www.jax.org/strain/search?query=COX4I2"},"sequence":{"accession":"Q96KJ9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96KJ9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96KJ9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96KJ9"}},"corpus_meta":[{"pmid":"36683245","id":"PMC_36683245","title":"Reprogramming of Mitochondrial Respiratory Chain Complex by Targeting SIRT3-COX4I2 Axis Attenuates Osteoarthritis Progression.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36683245","citation_count":74,"is_preprint":false},{"pmid":"19268275","id":"PMC_19268275","title":"Exocrine pancreatic insufficiency, dyserythropoeitic anemia, and calvarial hyperostosis are caused by a mutation in the COX4I2 gene.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19268275","citation_count":61,"is_preprint":false},{"pmid":"21059062","id":"PMC_21059062","title":"Association of sequence variants in CKM (creatine kinase, muscle) and COX4I2 (cytochrome c oxidase, subunit 4, isoform 2) genes with racing performance in Thoroughbred horses.","date":"2010","source":"Equine veterinary journal. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/21059062","citation_count":41,"is_preprint":false},{"pmid":"34026834","id":"PMC_34026834","title":"Cox4i2 Triggers an Increase in Reactive Oxygen Species, Leading to Ferroptosis and Apoptosis in HHV7 Infected Schwann Cells.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34026834","citation_count":21,"is_preprint":false},{"pmid":"36064310","id":"PMC_36064310","title":"Identification of COX4I2 as a hypoxia-associated gene acting through FGF1 to promote EMT and angiogenesis in CRC.","date":"2022","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/36064310","citation_count":20,"is_preprint":false},{"pmid":"39002521","id":"PMC_39002521","title":"EBF1-COX4I2 signaling axis promotes a myofibroblast-like phenotype in cancer-associated fibroblasts (CAFs) and is associated with an immunosuppressive microenvironment.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39002521","citation_count":10,"is_preprint":false},{"pmid":"36172142","id":"PMC_36172142","title":"Fibroblasts mediate the angiogenesis of pheochromocytoma by increasing COX4I2 expression.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36172142","citation_count":9,"is_preprint":false},{"pmid":"26263558","id":"PMC_26263558","title":"Cox4i2, Ifit2, and Prdm11 Mutant Mice: Effective Selection of Genes Predisposing to an Altered Airway Inflammatory Response from a Large Compendium of Mutant Mouse Lines.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26263558","citation_count":7,"is_preprint":false},{"pmid":"38422899","id":"PMC_38422899","title":"HIF1A transcriptional regulation of COX4I2 impacts angiogenesis in pheochromocytoma.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38422899","citation_count":4,"is_preprint":false},{"pmid":"34430392","id":"PMC_34430392","title":"COX4I2 is a novel biomarker of blood supply in adrenal tumors.","date":"2021","source":"Translational andrology and urology","url":"https://pubmed.ncbi.nlm.nih.gov/34430392","citation_count":3,"is_preprint":false},{"pmid":"36379384","id":"PMC_36379384","title":"A SNP of the COX4I2 gene associated with environmental adaptation in Chinese cattle.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/36379384","citation_count":1,"is_preprint":false},{"pmid":"40777413","id":"PMC_40777413","title":"Rpl13a snoRNAs Downregulate Smooth Muscle Cell COX4I2 and Promote Neointimal Hyperplasia.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40777413","citation_count":0,"is_preprint":false},{"pmid":"40977891","id":"PMC_40977891","title":"Multi-transcriptomics analysis of ferroptosis related genes reveals CAFs exosomal COX4I2 as a novel therapeutic target in osteosarcoma.","date":"2025","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/40977891","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.23.666475","title":"<i>Rpl13a</i> snoRNAs Downregulate Smooth Muscle Cell COX4I2 and Promote Neointimal Hyperplasia","date":"2025-07-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.23.666475","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.08.663799","title":"NDUFS2 (NADH:Ubiquinone oxidoreductase core subunit S2) in Mitochondrial Electron Transport Chain Complex I is Critical to Oxygen Responsiveness of Human Ductus Arteriosus Smooth Muscle Cells","date":"2025-07-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.08.663799","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.10.594693","title":"Convergent genetic adaptation in human tumors developed under systemic hypoxia and in populations living at high altitudes","date":"2024-06-12","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.10.594693","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10381,"output_tokens":2077,"usd":0.031149},"stage2":{"model":"claude-opus-4-6","input_tokens":5349,"output_tokens":2242,"usd":0.124192},"total_usd":0.155341,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"COX4I2 is an essential structural subunit of cytochrome c oxidase (Complex IV) with tissue-specific expression; its ratio to COX4I1 is relatively high in human acinar cells, and loss-of-function mutation causes marked reduction of COX4I2 expression and striking attenuation of the physiologic COX4I2 hypoxic response, linking it to mitochondrial respiratory chain function.\",\n      \"method\": \"Homozygosity mapping, mRNA expression analysis, mutation analysis in patient-derived cells\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct genetic and expression evidence in human patients with defined loss-of-function phenotype, replicated across four patients\",\n      \"pmids\": [\"19268275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SIRT3 deacetylates COX4I2 as a post-translational modification to maintain mitochondrial respiratory chain homeostasis; loss of SIRT3 leads to hyperacetylation of COX4I2 and impaired mitochondrial function, accelerating osteoarthritis progression.\",\n      \"method\": \"Co-immunoprecipitation, deacetylation assay, SIRT3 global knockout mice, honokiol-mediated SIRT3 activation rescue experiments\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP identifying SIRT3 as the writer for COX4I2 deacetylation, combined with in vivo KO phenotype and pharmacological rescue\",\n      \"pmids\": [\"36683245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cox4i2 increases COX (cytochrome c oxidase) activity in Schwann cells, thereby promoting ROS production; knockdown of Cox4i2 reduces oxidative stress, attenuates ferroptosis and apoptosis via the ERK signaling pathway in HHV7-infected Schwann cells.\",\n      \"method\": \"shRNA knockdown, ROS level measurement, MDA/SOD/GSH assays, cell death and proliferation assays, ERK pathway analysis in vitro and in vivo rat model\",\n      \"journal\": \"Frontiers in molecular biosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with defined cellular phenotype and pathway placement (ERK), but single lab study\",\n      \"pmids\": [\"34026834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HIF1A transcriptionally regulates COX4I2 expression by binding to its promoter; activation of HIF1A upregulates COX4I2, and this axis promotes angiogenesis through fibroblasts (not tumor cells directly) in pheochromocytoma.\",\n      \"method\": \"Dual luciferase reporter assay, siRNA knockdown, HIF1A inhibitor, hypoxia (1% O2) activation, conditioned medium tube formation and transwell assays in HUVECs, RNA sequencing\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter assay directly demonstrates HIF1A binding to COX4I2 promoter, with functional angiogenesis readout; single lab\",\n      \"pmids\": [\"38422899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Rpl13a snoRNA U32A guides 2'-O-methylation of COX4I2 mRNA, reducing COX4I2 protein levels post-transcriptionally without changing mRNA levels; loss of snoRNA U32A increases COX4I2 protein, reduces mitochondrial ROS in smooth muscle cells, and attenuates neointimal hyperplasia; silencing Cox4i2 in snoKO SMCs restores ROS to wild-type levels.\",\n      \"method\": \"snoRNA knockout mice (carotid endothelial denudation model), HEK293T snoRNA-specific deletion cells, 2'-O-methylation assay, siRNA silencing of Cox4i2, proteomics, Western blot, qPCR\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (snoKO + Cox4i2 silencing rescue), direct 2'-O-methylation mechanistic assay, and in vivo neointimal hyperplasia model; preprint only\",\n      \"pmids\": [\"40777413\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"EBF1 transcriptionally upregulates COX4I2 expression in cancer-associated fibroblasts (CAFs); COX4I2+ CAFs exhibit inhibited mitochondrial respiration and enhanced glycolysis, adopt a myofibroblast-like phenotype, promote immunosuppressive tumor microenvironment, and activate M2 macrophage polarization.\",\n      \"method\": \"Luciferase reporter assay, transcriptome sequencing, functional in vitro experiments (CD8+ T cell infiltration assay), clinical specimens\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — luciferase reporter validates EBF1-COX4I2 transcriptional axis; functional cellular phenotypes measured; single lab\",\n      \"pmids\": [\"39002521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"COX4I2 expressed in fibroblasts (not tumor cells) mediates angiogenesis in pheochromocytoma; knockdown of COX4I2 in NIH3T3 fibroblasts significantly reduces expression of angiogenesis-related genes ANG1 and HGF.\",\n      \"method\": \"scRNA-seq, immunostaining, siRNA knockdown in NIH3T3 cells, qPCR for angiogenesis-related genes\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, KD with gene expression readout but limited mechanistic depth\",\n      \"pmids\": [\"36172142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Exosome-mediated delivery of COX4I2 protein from cancer-associated fibroblasts to osteosarcoma cells suppresses ferroptosis (reduces Fe2+, MDA, ACSL4, and ROS levels) and enhances tumor cell proliferation and mitochondrial integrity in vitro and in vivo.\",\n      \"method\": \"Western blot, confocal microscopy, transmission electron microscopy (exosome characterization), ferroptosis marker assays, tumorigenicity assays in nude mice\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including in vivo validation and direct exosomal transfer demonstration; single lab\",\n      \"pmids\": [\"40977891\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"COX4I2 is an isoform-specific structural subunit of mitochondrial cytochrome c oxidase (Complex IV) that modulates electron transport chain activity and ROS production; it is transcriptionally induced by HIF1A and EBF1 under hypoxia, post-translationally regulated by SIRT3-mediated deacetylation, and post-transcriptionally suppressed by Rpl13a snoRNA U32A-guided 2'-O-methylation of its mRNA, with its activity in fibroblasts promoting angiogenesis and its activity in multiple cell types influencing ferroptosis, apoptosis, and mitochondrial homeostasis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"COX4I2 is a tissue-specific isoform of the nuclear-encoded subunit IV of mitochondrial cytochrome c oxidase (Complex IV) that modulates electron transport chain activity and reactive oxygen species (ROS) production. Its expression is transcriptionally regulated by HIF1A under hypoxia and by EBF1 in cancer-associated fibroblasts, post-translationally controlled by SIRT3-mediated deacetylation that maintains mitochondrial respiratory homeostasis, and post-transcriptionally suppressed by Rpl13a snoRNA U32A-guided 2′-O-methylation of its mRNA [PMID:19268275, PMID:38422899, PMID:39002521, PMID:36683245, PMID:40777413]. Through its regulation of COX activity and ROS levels, COX4I2 influences ferroptosis, apoptosis, and angiogenesis in cell-type-specific contexts: it promotes ROS-driven ferroptosis in Schwann cells via ERK signaling, drives fibroblast-mediated angiogenesis in pheochromocytoma, and when delivered by exosomes from cancer-associated fibroblasts suppresses ferroptosis in osteosarcoma cells [PMID:34026834, PMID:36172142, PMID:40977891]. Loss-of-function mutations in COX4I2 cause pancreatic acinic cell dysplasia with attenuated hypoxic COX4I2 induction [PMID:19268275].\",\n  \"teleology\": [\n    {\n      \"year\": 2009,\n      \"claim\": \"Establishing that COX4I2 is an essential, tissue-specific Complex IV subunit whose loss-of-function causes human disease resolved the question of whether isoform-specific subunits have non-redundant physiological roles in the mitochondrial respiratory chain.\",\n      \"evidence\": \"Homozygosity mapping and mutation analysis in four patients with pancreatic acinic cell dysplasia showing marked COX4I2 reduction and loss of hypoxic response\",\n      \"pmids\": [\"19268275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The structural basis for how COX4I2 differs functionally from COX4I1 at the atomic level is unresolved\",\n        \"Whether the hypoxic response of COX4I2 is solely transcriptional or also involves protein stabilization was not dissected\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that COX4I2 promotes ROS production and downstream ferroptosis/apoptosis via ERK signaling in Schwann cells established a mechanistic link between this Complex IV subunit and programmed cell death pathways.\",\n      \"evidence\": \"shRNA knockdown of Cox4i2 in HHV7-infected Schwann cells with ROS, MDA/SOD/GSH, cell death, and ERK pathway measurements\",\n      \"pmids\": [\"34026834\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether COX4I2 directly alters ERK signaling or does so indirectly through ROS is not resolved\",\n        \"Relevance beyond the HHV7 infection context has not been tested\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identifying COX4I2 expression specifically in fibroblasts (not tumor cells) as a mediator of angiogenesis in pheochromocytoma revealed an unexpected non-cell-autonomous role for a respiratory chain subunit in paracrine vascular regulation.\",\n      \"evidence\": \"scRNA-seq and siRNA knockdown in NIH3T3 fibroblasts measuring ANG1 and HGF expression\",\n      \"pmids\": [\"36172142\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Limited mechanistic depth: only qPCR readout for two genes without direct angiogenesis functional assay\",\n        \"The mechanism by which COX4I2 regulates ANG1/HGF transcription is unknown\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showing that SIRT3 deacetylates COX4I2 and that hyperacetylation impairs mitochondrial function identified a key post-translational regulatory axis controlling Complex IV activity.\",\n      \"evidence\": \"Reciprocal Co-IP, deacetylation assays, SIRT3 knockout mice with osteoarthritis phenotype, and honokiol pharmacological rescue\",\n      \"pmids\": [\"36683245\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The specific lysine residue(s) on COX4I2 targeted by SIRT3 are not mapped\",\n        \"Whether acetylation affects COX4I2 assembly into Complex IV or its catalytic function is unresolved\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrating that HIF1A directly binds the COX4I2 promoter and that EBF1 independently activates COX4I2 transcription defined dual transcriptional inputs that control COX4I2 in hypoxia and in the tumor microenvironment, respectively.\",\n      \"evidence\": \"Dual luciferase reporter assays for both HIF1A and EBF1 on the COX4I2 promoter; siRNA and inhibitor experiments; conditioned medium angiogenesis assays (HIF1A); transcriptome sequencing and immune cell infiltration assays (EBF1)\",\n      \"pmids\": [\"38422899\", \"39002521\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether HIF1A and EBF1 act on the same or distinct promoter elements is not resolved\",\n        \"How COX4I2 upregulation in fibroblasts switches metabolism toward glycolysis (EBF1 axis) is mechanistically unclear\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying snoRNA U32A-guided 2′-O-methylation of COX4I2 mRNA as a translational repression mechanism, and showing exosome-mediated intercellular transfer of COX4I2 protein, expanded the regulatory landscape to post-transcriptional and non-cell-autonomous dimensions.\",\n      \"evidence\": \"snoRNA knockout mice and HEK293T cells with 2′-O-methylation assays and Cox4i2 epistasis experiments (U32A); exosome isolation, confocal imaging, ferroptosis marker assays, and nude mouse tumorigenicity (exosomal transfer)\",\n      \"pmids\": [\"40777413\", \"40977891\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The U32A/COX4I2 mRNA methylation finding is from a preprint and awaits peer review\",\n        \"The precise methylation site(s) on COX4I2 mRNA and the ribosomal mechanism of translational suppression are not defined\",\n        \"Whether exosomal COX4I2 integrates into recipient cell Complex IV or functions independently is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How COX4I2 structurally integrates into Complex IV differently from COX4I1 to generate distinct ROS outputs, and how its context-dependent effects on ferroptosis (pro- vs. anti-ferroptotic) are determined, remain open questions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No structural model distinguishing COX4I2 from COX4I1 within assembled Complex IV\",\n        \"Opposing effects on ferroptosis across cell types (promoting in Schwann cells, suppressing in osteosarcoma) lack a unifying mechanistic explanation\",\n        \"The full acetylation site map and its effect on COX4I2 assembly and activity is uncharacterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 2, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 2, 4]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 7]}\n    ],\n    \"complexes\": [\n      \"Cytochrome c oxidase (Complex IV)\"\n    ],\n    \"partners\": [\n      \"SIRT3\",\n      \"HIF1A\",\n      \"EBF1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}